Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1955 1
1959 5
1969 1
1970 1
1971 1
1972 1
1973 1
1974 2
1975 5
1976 4
1977 4
1978 3
1979 3
1980 2
1981 3
1982 1
1983 3
1984 3
1985 7
1986 5
1987 4
1988 4
1989 10
1990 5
1991 7
1992 7
1993 11
1994 17
1995 23
1996 14
1997 22
1998 29
1999 27
2000 23
2001 21
2002 24
2003 27
2004 39
2005 40
2006 41
2007 34
2008 46
2009 51
2010 62
2011 94
2012 79
2013 76
2014 82
2015 69
2016 70
2017 75
2018 62
2019 74
2020 81
2021 111
2022 101
2023 58
2024 61

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,545 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT. Kang YK, et al. Among authors: yeh kh. Lancet. 2017 Dec 2;390(10111):2461-2471. doi: 10.1016/S0140-6736(17)31827-5. Epub 2017 Oct 6. Lancet. 2017. PMID: 28993052 Clinical Trial.
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data.
Chen LT, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Sameshima H, Kang YK, Boku N. Chen LT, et al. Among authors: yeh kh. Gastric Cancer. 2020 May;23(3):510-519. doi: 10.1007/s10120-019-01034-7. Epub 2019 Dec 20. Gastric Cancer. 2020. PMID: 31863227 Free PMC article. Clinical Trial.
Dasatinib-related chylothorax.
Huang YM, Wang CH, Huang JS, Yeh KY, Lai CH, Wu TH, Chang PH, Chang PH, Chang YS, Lan YJ. Huang YM, et al. Among authors: yeh ky. Turk J Haematol. 2015 Mar 5;32(1):68-72. doi: 10.4274/tjh.2012.0196. Turk J Haematol. 2015. PMID: 25805678 Free PMC article.
Endometrial adenosarcoma.
Huang RH, Chu PY, Yeh KT, Hsu JC. Huang RH, et al. Among authors: yeh kt. Taiwan J Obstet Gynecol. 2008 Sep;47(3):343-5. doi: 10.1016/S1028-4559(08)60138-2. Taiwan J Obstet Gynecol. 2008. PMID: 18936003 Free article. No abstract available.
ctDNA-based molecular residual disease and survival in resectable colorectal cancer.
Nakamura Y, Watanabe J, Akazawa N, Hirata K, Kataoka K, Yokota M, Kato K, Kotaka M, Kagawa Y, Yeh KH, Mishima S, Yukami H, Ando K, Miyo M, Misumi T, Yamazaki K, Ebi H, Okita K, Hamabe A, Sokuoka H, Kobayashi S, Laliotis G, Aushev VN, Sharma S, Jurdi A, Liu MC, Aleshin A, Rabinowitz M, Bando H, Taniguchi H, Takemasa I, Kato T, Kotani D, Mori M, Yoshino T, Oki E. Nakamura Y, et al. Among authors: yeh kh. Nat Med. 2024 Nov;30(11):3272-3283. doi: 10.1038/s41591-024-03254-6. Epub 2024 Sep 16. Nat Med. 2024. PMID: 39284954 Free PMC article.
1,545 results